A novel epidermal growth factor receptor inhibitor for treating lung cancer

To investigate the effects of a novel synthetic epidermal growth factor receptor inhibitor, COMPOUND7809, on the inhibition of lung cancer growth in vitro and the underlying mechanisms, we treated three lung tumor cell lines (A549, SK-LU-1, and NCI-H23) with COMPOUND7809 and a Food and Drug Administ...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2017-04, Vol.39 (4), p.1010428317698358-1010428317698358
Main Authors: Gao, Jiansheng, Liang, Yuli, Zhang, Dongying, Wang, Yi, Yang, Jiamin, Liu, Hua
Format: Article
Language:English
Subjects:
5-Fluorouracil
A549 Cells
Annexin V
Antineoplastic Agents - administration & dosage
Apoptosis
Apoptosis - drug effects
Cancer therapies
Cell death
Cell growth
Cell Proliferation - drug effects
Cell survival
Epidermal growth factor
Flow cytometry
Gefitinib
Humans
Inhibitor drugs
Kinases
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Phenyl Ethers - administration & dosage
Piperazines - administration & dosage
Protein Kinase Inhibitors - administration & dosage
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Signal Transduction - drug effects
Targeted cancer therapy
Tetrazolium Salts - administration & dosage
Thiazoles - administration & dosage
Tumor cell lines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the effects of a novel synthetic epidermal growth factor receptor inhibitor, COMPOUND7809, on the inhibition of lung cancer growth in vitro and the underlying mechanisms, we treated three lung tumor cell lines (A549, SK-LU-1, and NCI-H23) with COMPOUND7809 and a Food and Drug Administration–approved epidermal growth factor receptor inhibitor gefitinib. Then, we examined cell growth in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, cell survival in a Cell Counting Kit-8 assay, and cell apoptosis by Annexin V flow cytometry in the presence of fluorouracil. We found that compared to gefitinib, COMPOUND7809 inhibited cell growth more potentially and induced more cell death in the presence of fluorouracil. Thus, our study demonstrates that COMPOUND7809 may be a promising epidermal growth factor receptor inhibitor for human lung cancer therapy.
ISSN:1010-4283
1423-0380
DOI:10.1177/1010428317698358